全文获取类型
收费全文 | 24950篇 |
免费 | 2293篇 |
国内免费 | 1277篇 |
专业分类
耳鼻咽喉 | 87篇 |
儿科学 | 590篇 |
妇产科学 | 66篇 |
基础医学 | 3273篇 |
口腔科学 | 312篇 |
临床医学 | 2405篇 |
内科学 | 7740篇 |
皮肤病学 | 402篇 |
神经病学 | 473篇 |
特种医学 | 614篇 |
外科学 | 2703篇 |
综合类 | 3433篇 |
现状与发展 | 3篇 |
预防医学 | 834篇 |
眼科学 | 144篇 |
药学 | 2674篇 |
7篇 | |
中国医学 | 2467篇 |
肿瘤学 | 293篇 |
出版年
2024年 | 95篇 |
2023年 | 667篇 |
2022年 | 1321篇 |
2021年 | 1453篇 |
2020年 | 1444篇 |
2019年 | 1200篇 |
2018年 | 1118篇 |
2017年 | 1193篇 |
2016年 | 1064篇 |
2015年 | 947篇 |
2014年 | 1969篇 |
2013年 | 2647篇 |
2012年 | 1338篇 |
2011年 | 1480篇 |
2010年 | 1061篇 |
2009年 | 1110篇 |
2008年 | 1122篇 |
2007年 | 1152篇 |
2006年 | 911篇 |
2005年 | 699篇 |
2004年 | 596篇 |
2003年 | 430篇 |
2002年 | 412篇 |
2001年 | 328篇 |
2000年 | 313篇 |
1999年 | 287篇 |
1998年 | 280篇 |
1997年 | 215篇 |
1996年 | 213篇 |
1995年 | 185篇 |
1994年 | 156篇 |
1993年 | 162篇 |
1992年 | 137篇 |
1991年 | 95篇 |
1990年 | 95篇 |
1989年 | 65篇 |
1988年 | 64篇 |
1987年 | 68篇 |
1986年 | 67篇 |
1985年 | 56篇 |
1984年 | 64篇 |
1983年 | 34篇 |
1982年 | 60篇 |
1981年 | 40篇 |
1980年 | 25篇 |
1979年 | 19篇 |
1978年 | 16篇 |
1977年 | 12篇 |
1976年 | 13篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
4.
《Journal of infection and chemotherapy》2022,28(4):587-590
A 37-year-old man developed right ankle pain and swelling six days after being diagnosed with coronavirus disease (COVID-19). Despite conservative treatment, his ankle symptoms persisted. Magnetic resonance imaging and computed tomography showed synovial hypertrophy and bone erosion in the ankle. Following arthroscopic synovectomy, performed 69 days after the COVID-19 diagnosis, the pain improved significantly. The clinical course was consistent with that of reactive arthritis following severe acute respiratory syndrome coronavirus 2 infection. The pathological findings resembled rheumatoid nodules. The bone erosion may have originated from the inflammatory pathway, which resembles the mechanism of rheumatoid arthritis. 相似文献
5.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
6.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
7.
8.
9.
10.